CD8A and neoplasm: Applying TEXomiR, on one hand, took advantage of the unique feature of tumor exosomes carrying a broad spectrum of tumor antigens that could stimulate antigen-specific immune responses from both Th1 (CD4+ T cells) and CD8 cytotoxic T cells (CD8+ T cells), thus leading to an amplified immunotherapeutic effect of TEXomiR.